Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
| Image |  |
|---|---|
| Description | scientific article published on 2 January 2012 |
| Author/s |
author: Kuen-Feng Chen Chen Pei-jer Ann-Lii Cheng |
| Publication date | January 2, 2012 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |